Cargando…
A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron
COVID-19 caused, as of September, 1rst, 2022, 599,825,400 confirmed cases, including 6,469,458 deaths. Currently used vaccines reduced severity and mortality but not virus transmission or reinfection by different strains. They are based on the Spike protein of the Wuhan reference virus, which althou...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537284/ https://www.ncbi.nlm.nih.gov/pubmed/36202985 http://dx.doi.org/10.1038/s41598-022-21207-2 |
_version_ | 1784803166103011328 |
---|---|
author | Palatnik-de-Sousa, Iam Wallace, Zachary S. Cavalcante, Stephany Christiny Ribeiro, Maria Paula Fonseca Silva, João Antônio Barbosa Martins Cavalcante, Rafael Ciro Scheuermann, Richard H. Palatnik-de-Sousa, Clarisa Beatriz |
author_facet | Palatnik-de-Sousa, Iam Wallace, Zachary S. Cavalcante, Stephany Christiny Ribeiro, Maria Paula Fonseca Silva, João Antônio Barbosa Martins Cavalcante, Rafael Ciro Scheuermann, Richard H. Palatnik-de-Sousa, Clarisa Beatriz |
author_sort | Palatnik-de-Sousa, Iam |
collection | PubMed |
description | COVID-19 caused, as of September, 1rst, 2022, 599,825,400 confirmed cases, including 6,469,458 deaths. Currently used vaccines reduced severity and mortality but not virus transmission or reinfection by different strains. They are based on the Spike protein of the Wuhan reference virus, which although highly antigenic suffered many mutations in SARS-CoV-2 variants, escaping vaccine-generated immune responses. Multiepitope vaccines based on 100% conserved epitopes of multiple proteins of all SARS-CoV-2 variants, rather than a single highly mutating antigen, could offer more long-lasting protection. In this study, a multiepitope multivariant vaccine was designed using immunoinformatics and in silico approaches. It is composed of highly promiscuous and strong HLA binding CD4(+) and CD8(+) T cell epitopes of the S, M, N, E, ORF1ab, ORF 6 and ORF8 proteins. Based on the analysis of one genome per WHO clade, the epitopes were 100% conserved among the Wuhan-Hu1, Alpha, Beta, Gamma, Delta, Omicron, Mµ, Zeta, Lambda and R1 variants. An extended epitope-conservancy analysis performed using GISAID metadata of 3,630,666 SARS-CoV-2 genomes of these variants and the additional genomes of the Epsilon, Lota, Theta, Eta, Kappa and GH490 R clades, confirmed the high conservancy of the epitopes. All but one of the CD4 peptides showed a level of conservation greater than 97% among all genomes. All but one of the CD8 epitopes showed a level of conservation greater than 96% among all genomes, with the vast majority greater than 99%. A multiepitope and multivariant recombinant vaccine was designed and it was stable, mildly hydrophobic and non-toxic. The vaccine has good molecular docking with TLR4 and promoted, without adjuvant, strong B and Th1 memory immune responses and secretion of high levels of IL-2, IFN-γ, lower levels of IL-12, TGF-β and IL-10, and no IL-6. Experimental in vivo studies should validate the vaccine’s further use as preventive tool with cross-protective properties. |
format | Online Article Text |
id | pubmed-9537284 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-95372842022-10-08 A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron Palatnik-de-Sousa, Iam Wallace, Zachary S. Cavalcante, Stephany Christiny Ribeiro, Maria Paula Fonseca Silva, João Antônio Barbosa Martins Cavalcante, Rafael Ciro Scheuermann, Richard H. Palatnik-de-Sousa, Clarisa Beatriz Sci Rep Article COVID-19 caused, as of September, 1rst, 2022, 599,825,400 confirmed cases, including 6,469,458 deaths. Currently used vaccines reduced severity and mortality but not virus transmission or reinfection by different strains. They are based on the Spike protein of the Wuhan reference virus, which although highly antigenic suffered many mutations in SARS-CoV-2 variants, escaping vaccine-generated immune responses. Multiepitope vaccines based on 100% conserved epitopes of multiple proteins of all SARS-CoV-2 variants, rather than a single highly mutating antigen, could offer more long-lasting protection. In this study, a multiepitope multivariant vaccine was designed using immunoinformatics and in silico approaches. It is composed of highly promiscuous and strong HLA binding CD4(+) and CD8(+) T cell epitopes of the S, M, N, E, ORF1ab, ORF 6 and ORF8 proteins. Based on the analysis of one genome per WHO clade, the epitopes were 100% conserved among the Wuhan-Hu1, Alpha, Beta, Gamma, Delta, Omicron, Mµ, Zeta, Lambda and R1 variants. An extended epitope-conservancy analysis performed using GISAID metadata of 3,630,666 SARS-CoV-2 genomes of these variants and the additional genomes of the Epsilon, Lota, Theta, Eta, Kappa and GH490 R clades, confirmed the high conservancy of the epitopes. All but one of the CD4 peptides showed a level of conservation greater than 97% among all genomes. All but one of the CD8 epitopes showed a level of conservation greater than 96% among all genomes, with the vast majority greater than 99%. A multiepitope and multivariant recombinant vaccine was designed and it was stable, mildly hydrophobic and non-toxic. The vaccine has good molecular docking with TLR4 and promoted, without adjuvant, strong B and Th1 memory immune responses and secretion of high levels of IL-2, IFN-γ, lower levels of IL-12, TGF-β and IL-10, and no IL-6. Experimental in vivo studies should validate the vaccine’s further use as preventive tool with cross-protective properties. Nature Publishing Group UK 2022-10-06 /pmc/articles/PMC9537284/ /pubmed/36202985 http://dx.doi.org/10.1038/s41598-022-21207-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Palatnik-de-Sousa, Iam Wallace, Zachary S. Cavalcante, Stephany Christiny Ribeiro, Maria Paula Fonseca Silva, João Antônio Barbosa Martins Cavalcante, Rafael Ciro Scheuermann, Richard H. Palatnik-de-Sousa, Clarisa Beatriz A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron |
title | A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron |
title_full | A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron |
title_fullStr | A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron |
title_full_unstemmed | A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron |
title_short | A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron |
title_sort | novel vaccine based on sars-cov-2 cd4(+) and cd8(+) t cell conserved epitopes from variants alpha to omicron |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537284/ https://www.ncbi.nlm.nih.gov/pubmed/36202985 http://dx.doi.org/10.1038/s41598-022-21207-2 |
work_keys_str_mv | AT palatnikdesousaiam anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT wallacezacharys anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT cavalcantestephanychristiny anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT ribeiromariapaulafonseca anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT silvajoaoantoniobarbosamartins anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT cavalcanterafaelciro anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT scheuermannrichardh anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT palatnikdesousaclarisabeatriz anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT palatnikdesousaiam novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT wallacezacharys novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT cavalcantestephanychristiny novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT ribeiromariapaulafonseca novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT silvajoaoantoniobarbosamartins novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT cavalcanterafaelciro novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT scheuermannrichardh novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron AT palatnikdesousaclarisabeatriz novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron |